Simultaneous assay of olanzapine and fluoxetine in tablets by column high-performance liquid chromatography and high-performance thin-layer chromatography.
This paper describes validated high-performance liquid chromatographic (LC) and high-performance thin-layer chromatographic (TLC) methods for the simultaneous estimation of olanzapine and fluoxetine in pure powder and tablet formulations. The LC separation was achieved on a Lichrospher 100 RP-180, C18 column (250 mm, 4.0 mm id, 5 microm) using 0.05 M potassium dihydrogen phosphate buffer (pH 5.6 adjusted with o-phosphoric acid)-acetonitrile (50 + 50, v/v) as the mobile phase at a flow rate of 1 mL/min and ambient temperature. The TLC separation was achieved on aluminum sheets coated with silica gel 60F254 using methanol-toluene (40 + 20, v/v) as the mobile phase. Quantitation was achieved by measuring ultraviolet absorption at 233 nm over the concentration range of 10-70 and 40-280 microg/mL with mean recovery of 99.54 +/- 0.89 and 99.73 +/- 0.58% for olanzapine and fluoxetine, respectively, by the LC method. Quantitation was achieved by measuring ultraviolet absorption at 233 nm over the concentration range of 100-800 and 400-3200 ng/spot with mean recovery of 101.53 +/- 0.06 and 101.45 +/- 0.35% for olanzapine and fluoxetine, respectively, by the TLC method with densitometry. These methods are simple, precise, and sensitive, and they are applicable for simultaneous determination of olanzapine and fluoxetine in tablet formulations.
Shah
Charmy R
CR
Shri B.M. Shah College of Pharmaceutical Education and Research, Department of Pharmaceutical Chemistry, College Campus, Modasa-383315, Gujarat, India. crshah681@yahoo.com
Shah
Nehal J
NJ
Suhagia
Bhanubhai N
BN
Patel
Natvarlal M
NM
D014150:Antipsychotic Agents / Q000032:analysis*; D001569:Benzodiazepines / Q000032:analysis*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D005473:Fluoxetine / Q000032:analysis*; D000077152:Olanzapine; D011208:Powders; D012015:Reference Standards; D015203:Reproducibility of Results; D017367:Selective Serotonin Reuptake Inhibitors / Q000032:analysis*; D013607:Tablets
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D005473:Fluoxetine; D000077152:Olanzapine; D011208:Powders; D017367:Selective Serotonin Reuptake Inhibitors; D013607:Tablets